Restricted accessResearch articleFirst published online 2017-09
Short Communication: Manα1-2Man-Binding Anti-HIV Lectins Enhance the Exposure of V2i and V3 Crown Neutralization Epitopes on the V1/V2 and V3 Hypervariable Loops of HIV-1 Envelope
This study aimed to explore the contribution of high-mannose glycans in the masking of conserved V3 crown (GPG) and V2i epitopes on the hypervariable loops of most exposed distal surface of HIV-1 Env. Using lectins specific to Manα1-2Man residue containing Man6-9GlcNAc2 glycans extensively decorating HIV-1 Env, we found that Manα1-2Man-binding lectins enhance the exposure of these partially and transiently exposed epitopes and consequentially increase the neutralization strength of antibodies against these epitopes.
Get full access to this article
View all access options for this article.
References
1.
DooresKJ, BonomelliC, HarveyDJ, VasiljevicS, DwekRA, BurtonDR, CrispinM, ScanlanCN: Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A, 2010; 107:13800–13805.
2.
ReitterJN, MeansRE, DesrosiersRC: A role for carbohydrates in immune evasion in AIDS. Nat Med, 1998; 4:679–684.
SandersRW, DerkingR, CupoA, JulienJP, YasmeenA, de ValN, KimHJ, BlattnerC, de la PenaAT, KorzunJ, GolabekM, de Los ReyesK, KetasTJ, van GilsMJ, KingCR, WilsonIA, WardAB, KlassePJ, MooreJP: A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog, 2013; 9:e1003618.
5.
LetvinNL, RobinsonS, RohneD, AxthelmMK, FantonJW, BilskaM, PalkerTJ, LiaoHX, HaynesBF, MontefioriDC: Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. J Virol, 2001; 75:4165–4175.
6.
BinleyJM, BanYE, CrooksET, EgginkD, OsawaK, SchiefWR, SandersRW: Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol, 2010; 84:5637–5655.
7.
DooresKJ: The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J, 2015; 282:4679–4691.
8.
AlexandreKB, GrayES, LambsonBE, MoorePL, ChogeIA, MlisanaK, KarimSS, McMahonJ, O'KeefeB, ChikwambaR, MorrisL: Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology, 2010; 402:187–196.
9.
GornyMK, PanR, WilliamsC, WangXH, VolskyB, O'NealT, SpurrierB, SampsonJM, LiL, SeamanMS, KongXP, Zolla-PaznerS: Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology, 2012; 427:198–207.
10.
Zolla-PaznerS, CohenSS, BoydD, KongXP, SeamanM, NussenzweigM, KleinF, OverbaughJ, TotrovM: Structure/function studies involving the V3 region of the HIV-1 envelope delineate multiple factors that affect neutralization sensitivity. J Virol, 2016; 90:636–649.
11.
MontefioriDC: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol, 2005;Chapter 12:Unit 12.11.
GornyMK, MooreJP, ConleyAJ, KarwowskaS, SodroskiJ, WilliamsC, BurdaS, BootsLJ, Zolla-PaznerS: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol, 1994; 68:8312–8320.
